KoreaTechToday - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTechToday - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Celltrion

Celltrion to Conduct Trial of Remsima as COVID-19 Therapeutics in UK

 1,193 total views,  1 views today

James Jung by James Jung
PUBLISHED: June 10, 2020 UPDATED: June 11, 2020
in Celltrion, Coronavirus, South Korea, UK
0
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom.
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare

Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare

Celltrion Healthcare announced on Wednesday that it would commence clinical trials of Remsima, an anti-inflammatory biosimilar, on COVID-19 patients this month in the United Kingdom (UK).

Celltrion Healthcare is a distribution unit of leading Korean biopharmaceutical company, Celltrion Ltd., located at Incheon, South Korea.

The trial will take place in collaboration with four UK healthcare institutions, namely NIHR Birmingham Biomedical Research Center, Oxford NIHR BRC, University Hospital of Birmingham, and UCLH/UCL Biomedical Research Centre in London.

A company official said that the clinical trials include the use of Remsima, a clinically approved drug with anti-inflammatory properties immediately starting with Covid-19 patients. The trial aims to detect if the drug can be used to hinder inflammation in severe cases and enhance the recovery process of Covid-19 patients.

Sir Marc Feldmann, Senior Research Fellow at Somerville College and Immunology Professor at Oxford University, would lead the trials. According to Feldmann, tumor necrosis factor (TNF) could be found in the blood and tissues of Covid-19 patients. TNF acts as an amplifier of inflammation in patients, and thus an anti-TNF- α therapy should be used to treat COVID-19.

In an article published in the Lancet last April 9, 202, Feldmann said that an anti-TNF therapy should be assessed in COVID-19 patients upon admission to the hospital to inhibit the development of the disease and prevent the patient from transferring to intensive care support. An anti-TNF antibody should be given to patients two days after being admitted to the hospital to avoid exacerbation of viral pneumonia.

On the other hand, the utmost caution should be exercised in carrying out the clinical trial. According to Feldmann, there could be a possibility of a compromise between drug immunity and virus clearance with the use of a powerful anti-inflammatory drug. It could also lead to other bacterial infections while alleviating inflammation.

Celltrion Healthcare contacted Feldmann and proposed to supply him with the anti-TNF antibody Remsima for his research. Initially developed by Johnson & Johnson, Remsima is a biosimilar of Remicade, an infliximab used to treat Crohn’s disease and rheumatoid arthritis.

What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: CelltrionCelltrion Healthcareclinical trialsCOVID-19JuneMarc FeldmannRemsimatherapeuticsUK

Related Posts

Samsung headquarters
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare
South Korea

Korea’s top 100 companies’ economic contribution soar by 20%  in 9 years

July 20, 2022
South Korea curbs tech leaks to foreign countries
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare
South Korea

South Korea curbs tech leaks to foreign countries

February 8, 2022
Hyundai Rotem set to provide upgraded army tank variants to South Korea
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare
South Korea

Hyundai Rotem set to provide upgraded army tank variants to South Korea

February 2, 2022
S.Korea will track COVID-19 cases with AI-powered facial recognition from January
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare
South Korea

S.Korea will track COVID-19 cases with AI-powered facial recognition from January

December 14, 2021
South Korea sets site engineering standards for big tech firms
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare
Google

South Korea sets site engineering standards for big tech firms

December 9, 2021
National AI complex project starts in South Korea: New AI hub in making
Celltrion Healthcare announced that it would commence clinical trials of Remsima on COVID-19 patients this month in the United Kingdom. / photo courtesy of Celltrion Healthcare
South Korea

National AI complex project starts in South Korea: New AI hub in making

November 25, 2021
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Top Eight Promising EdTech Startup Companies in South Korea

    0 shares
    Share 0 Tweet 0
  • Top Nine Mobile MMORPG in South Korea for 2020

    0 shares
    Share 0 Tweet 0
  • Korean tech giants to focus on future innovations & sustainability actions at CES 2023 

    0 shares
    Share 0 Tweet 0
  • World’s First 5G Robot Café has a Seoul Opening

    0 shares
    Share 0 Tweet 0
  • Top 10 Must-Have Korean Apps You Need When Visiting in Korea

    0 shares
    Share 0 Tweet 0
  • Samsung SDS Secures Defense Mobile Security Solutions Order in Italy

    0 shares
    Share 0 Tweet 0
  • South Korea Improves Digital New Deal with the Data Dam Project

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2022 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2022 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy| Contact : [email protected] |